Marker Therapeutics

Focus: Marker Therapeutics is a Houston-based cell therapy and gene therapy biotechnology company focused on developing immunotherapies for cancer indications. The company operates as a mid-stage biotech with a diversified pipeline spanning hematologic and solid tumor malignancies.

Gene Therapy Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Marker Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Marker Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

19 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Quality of life questionnair

Incisional Hernia

N/A

Clinical Trials (1)

NCT06864377Ventral Hernia Improvement of Treatment and Life

N/A

Help build intelligence for Marker Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline diversity across Phase 1-2 with 3 Phase 2 programs (MT-401, TPIV200, FRα vaccine) providing near-term clinical catalysts in high-value oncology indications
Cell and gene therapy specialization offers deep technical expertise in cutting-edge modalities with significant unmet need in AML, ovarian, breast, and pancreatic cancers
Houston headquarters provides lower cost-of-living alternative to Boston/San Francisco biotech hubs with proximity to MD Anderson and Texas Medical Center research ecosystem

Watch Out For

Zero active job openings reported suggests company is in holding pattern or contraction phase, limiting near-term hiring visibility and career mobility
No marketed products and limited pipeline maturity (3 Phase 2, 3 Phase 1, zero Phase 3) creates extended runway to value inflection and revenue generation risk
Lack of disclosed funding, revenue, and employee headcount data indicates either private status with limited transparency or reduced scale compared to peer biotechs

Generated by Claude from Marker Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

blood sampling

Colorectal Cancer

N/A

Clinical Trials (1)

NCT06889844Observational Cross-reactivity Study for Colorectal Cancer Diagnosis

N/A

blood sampling

Colorectal Cancer Screening

N/A

Clinical Trials (1)

NCT06738511Validation of a Molecular Signature for Early Detection of Colorectal Cancer

N/A